These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27715904)

  • 41. A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder.
    Lopian KM; Chebolu E; Kulak JA; Kahn LS; Blondell RD
    J Subst Abuse Treat; 2019 Feb; 97():1-6. PubMed ID: 30577894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection.
    Walley AY; Palmisano J; Sorensen-Alawad A; Chaisson C; Raj A; Samet JH; Drainoni ML
    J Subst Abuse Treat; 2015 Dec; 59():59-66. PubMed ID: 26298399
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users.
    Cunningham CO; Giovanniello A; Kunins HV; Roose RJ; Fox AD; Sohler NL
    Am J Addict; 2013; 22(4):352-7. PubMed ID: 23795874
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retention in HIV care during the 3 years following release from incarceration: A cohort study.
    Loeliger KB; Meyer JP; Desai MM; Ciarleglio MM; Gallagher C; Altice FL
    PLoS Med; 2018 Oct; 15(10):e1002667. PubMed ID: 30300351
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.
    Bentzley BS; Barth KS; Back SE; Aronson G; Book SW
    J Subst Abuse Treat; 2015 Sep; 56():48-53. PubMed ID: 25899872
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 'Too little dose - too early discontinuation?'-Effect of buprenorphine dose on short term treatment adherence in opioid dependence.
    Muruganandam P; Shukla L; Sharma P; Kandasamy A; Chand P; Murthy P
    Asian J Psychiatr; 2019 Aug; 44():58-60. PubMed ID: 31325758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness.
    Fine DR; Lewis E; Weinstock K; Wright J; Gaeta JM; Baggett TP
    JAMA Netw Open; 2021 Mar; 4(3):e210477. PubMed ID: 33662132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes.
    Bentzley BS; Barth KS; Back SE; Book SW
    J Subst Abuse Treat; 2015 May; 52():48-57. PubMed ID: 25601365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees.
    Hammerslag LR; Mack A; Chandler RK; Fanucchi LC; Feaster DJ; LaRochelle MR; Lofwall MR; Nau M; Villani J; Walsh SL; Westgate PM; Slavova S; Talbert JC
    JAMA Netw Open; 2023 Oct; 6(10):e2336914. PubMed ID: 37851446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study.
    Selitsky L; Nordeck C; Truong A; Agus D; Buresh ME
    J Subst Use Addict Treat; 2023 Apr; 147():208981. PubMed ID: 36804350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pain is not associated with worse office-based buprenorphine treatment outcomes.
    Fox AD; Sohler NL; Starrels JL; Ning Y; Giovanniello A; Cunningham CO
    Subst Abus; 2012; 33(4):361-5. PubMed ID: 22989279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.
    Smith KE; Tillson MD; Staton M; Winston EM
    Drug Alcohol Depend; 2020 Mar; 208():107837. PubMed ID: 31951906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Criminal charges prior to and after initiation of office-based buprenorphine treatment.
    Harris EE; Jacapraro JS; Rastegar DA
    Subst Abuse Treat Prev Policy; 2012 Mar; 7():10. PubMed ID: 22429821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.